Efficacy and safety evaluation of rivaroxaban vs. warfarin among non-valvular atrial fibrillation patients undergoing lower extremity revascularization

Article Cardiac & Cardiovascular Systems

The WOEST 2 registry A prospective registry on antithrombotic therapy in atrial fibrillation patients undergoing percutaneous coronary intervention

A. J. W. M. de Veer et al.

Summary: Patients undergoing PCI with combined oral anticoagulation and antiplatelet therapy have a high risk of bleeding and ischemia. Over time, NOAC plus clopidogrel has become the preferred treatment.

NETHERLANDS HEART JOURNAL (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Evolving Antithrombotic Treatment Patterns for Patients With Nonvalvular Atrial Fibrillation and Acute Coronary Syndrome or Underwent Percutaneous Coronary Intervention in China: A Cross-Sectional Study

Ni Suo et al.

Summary: In China, there is a trend of decreasing dual antiplatelet therapy (DAPT) prescription and increasing use of triple therapy (TT)/double therapy (DT) for patients with nonvalvular atrial fibrillation concomitant with acute coronary syndrome or undergoing percutaneous coronary intervention. However, the appropriate antithrombotic regimen for these patients is still underused.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease

Hsin-Fu Lee et al.

Summary: A study comparing the effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) vs. warfarin in atrial fibrillation (AF) patients with peripheral artery disease (PAD) found that NOACs were associated with comparable risk of stroke but significantly lower risk of major adverse limb events and bleeding compared to warfarin, suggesting that NOACs may be a better option for these patients.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)

Gerhard Hindricks et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Surgery

Comparing Safety and Efficacy of Rivaroxaban with Warfarin for Patients after Successful Stent Placement for Chronic Iliofemoral Occlusion: A Retrospective Single Institution Study

Xing Zhang et al.

Summary: Rivaroxaban and warfarin showed similar safety in patients with post-thrombotic syndrome with chronic iliofemoral venous occlusion, but rivaroxaban demonstrated superior efficacy, particularly in terms of primary patency rate and symptom recurrence.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease

Anders Gottsaeter

Summary: This review focuses on the rationale for recommendations on antiplatelet and anticoagulant treatment in PAD patients, suggesting different medication treatment plans for patients with different symptoms, and the need to weigh the pros and cons based on individual circumstances.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)

Add to Collection

Article Hematology

What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg?

Sung Soo Kim et al.

Summary: In elderly Korean patients with atrial fibrillation, off-label reduced dose of rivaroxaban to 15 mg did not confer any benefits, thus guideline-adherent rivaroxaban 20 mg is more favorable in this population.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems